Actively Recruiting
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
Led by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Updated on 2025-11-24
430
Participants Needed
1
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main objective of this study is to compare the efficacy and safety of the triple combination therapy of Met/SGLT-2i/GLP-1RA or other oral antidiabetic drugs in patients with type 2 diabetes exhibiting poor glycemic control.
CONDITIONS
Official Title
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with type 2 diabetes according to Chinese guidelines (2020 edition)
- Age between 18 and 75 years, male or female
- Body mass index (BMI) of 20 kg/m² or higher
- Taking 1000 mg or more of metformin daily, with or without other oral diabetes drugs (excluding SGLT-2 inhibitors and GLP-1 receptor agonists), for at least 8 weeks before screening
- Poor blood sugar control with HbA1c between 7.5% and 11.0%
- Willing to participate and able to sign informed consent
You will not qualify if you...
- Diagnosed with type 1 diabetes or other special diabetes types
- Had ketoacidosis, hyperglycemic hyperosmolar state, or lactic acidosis within 6 months before screening
- Used GLP-1 receptor agonists or SGLT-2 inhibitors within 12 weeks before screening, or previously stopped these drugs due to poor effect
- Received insulin treatment within 1 week before screening
- History or current signs of pancreatitis, or fasting triglycerides above 5.7 mmol/L during screening
- Liver function tests showing ALT or AST above 3 times the upper normal limit, or bilirubin above 2 times the upper normal limit
- Kidney function impairment with eGFR below 45 mL/min/1.73m² or serum creatinine above 1.5 times the upper normal limit
- Past or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2
- Pregnant, breastfeeding, or planning pregnancy during the study
- Allergic or intolerant to metformin, ganagliflozin, liraglutide, or related ingredients
- Participated in another drug trial within 3 months before screening
- Unable to follow the study protocol or having serious physical or mental conditions affecting safety or effectiveness
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Actively Recruiting
Research Team
X
Xiaofen Qian
CONTACT
W
Wanting Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here